372 related articles for article (PubMed ID: 22422012)
1. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
Molloy ES; Calabrese LH
Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?
Molloy ES; Calabrese LH
Autoimmun Rev; 2008 Dec; 8(2):144-6. PubMed ID: 18700172
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.
Fleischmann RM
Arthritis Rheum; 2009 Nov; 60(11):3225-8. PubMed ID: 19877057
[TBL] [Abstract][Full Text] [Related]
4. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
Perez-Alvarez R; Perez-de-Lis M; Diaz-Lagares C; Pego-Reigosa JM; Retamozo S; Bove A; Brito-Zeron P; Bosch X; Ramos-Casals M
Semin Arthritis Rheum; 2011 Oct; 41(2):256-64. PubMed ID: 21277618
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy in autoimmune diseases.
Palazzo E; Yahia SA
Joint Bone Spine; 2012 Jul; 79(4):351-5. PubMed ID: 22281228
[TBL] [Abstract][Full Text] [Related]
6. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies.
Calabrese LH; Molloy ES
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii64-5. PubMed ID: 19022817
[TBL] [Abstract][Full Text] [Related]
8. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS).
Schmedt N; Andersohn F; Garbe E
Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1216-20. PubMed ID: 22821419
[TBL] [Abstract][Full Text] [Related]
9. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.
Kothary N; Diak IL; Brinker A; Bezabeh S; Avigan M; Dal Pan G
J Am Acad Dermatol; 2011 Sep; 65(3):546-551. PubMed ID: 21514689
[TBL] [Abstract][Full Text] [Related]
10. PML and rheumatology: the contribution of disease and drugs.
Molloy ES
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S28-32. PubMed ID: 22123931
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases.
Molloy ES; Calabrese LH
Arthritis Rheum; 2009 Dec; 60(12):3761-5. PubMed ID: 19950261
[TBL] [Abstract][Full Text] [Related]
12. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
García-Suárez J; de Miguel D; Krsnik I; Bañas H; Arribas I; Burgaleta C
Am J Hematol; 2005 Dec; 80(4):271-81. PubMed ID: 16315252
[TBL] [Abstract][Full Text] [Related]
13. The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management.
Molloy ES; Calabrese CM; Calabrese LH
Rheum Dis Clin North Am; 2017 Feb; 43(1):95-109. PubMed ID: 27890176
[TBL] [Abstract][Full Text] [Related]
14. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.
Boren EJ; Cheema GS; Naguwa SM; Ansari AA; Gershwin ME
J Autoimmun; 2008; 30(1-2):90-8. PubMed ID: 18191544
[TBL] [Abstract][Full Text] [Related]
15. Progressive multifocal leukoencephalopathy in a 27-year-old lady with systemic lupus erythematosus - rheumatoid arthritis overlap syndrome.
Cheng CF; Su JJ; Chen YF; Lin YC; Huang YM; Li KJ
J Formos Med Assoc; 2019 Nov; 118(11):1560-1565. PubMed ID: 31202498
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases.
Régnier-Rosencher E; Farhi D; Lebrun A; Salliot C; Dougados M; Dupin N
Dermatology; 2012; 224(1):72-83. PubMed ID: 22487697
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Carson KR; Evens AM; Richey EA; Habermann TM; Focosi D; Seymour JF; Laubach J; Bawn SD; Gordon LI; Winter JN; Furman RR; Vose JM; Zelenetz AD; Mamtani R; Raisch DW; Dorshimer GW; Rosen ST; Muro K; Gottardi-Littell NR; Talley RL; Sartor O; Green D; Major EO; Bennett CL
Blood; 2009 May; 113(20):4834-40. PubMed ID: 19264918
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.
Clifford DB; Ances B; Costello C; Rosen-Schmidt S; Andersson M; Parks D; Perry A; Yerra R; Schmidt R; Alvarez E; Tyler KL
Arch Neurol; 2011 Sep; 68(9):1156-64. PubMed ID: 21555606
[TBL] [Abstract][Full Text] [Related]
19. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.
Tesfa D; Ajeganova S; Hägglund H; Sander B; Fadeel B; Hafström I; Palmblad J
Arthritis Rheum; 2011 Aug; 63(8):2209-14. PubMed ID: 21560117
[TBL] [Abstract][Full Text] [Related]
20. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.
Piccinni C; Sacripanti C; Poluzzi E; Motola D; Magro L; Moretti U; Conforti A; Montanaro N
Eur J Clin Pharmacol; 2010 Feb; 66(2):199-206. PubMed ID: 19838692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
